CoChat
Sign Up
Cited by 75

The DOI matches its Crossref record.

Micro RNA -214,-150,-146a and-125b target Huntingtin gene

Sinha, Mithun, Ghose, Jayeeta, Bhattarcharyya, Nitai P.·2011·RNA Biology
DOI 10.4161/rna.8.6.16035
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/rna.8.6.16035

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 51

  1. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995; 81:811-23; PMID:7774020; DOI:10.1016/0092-8674(95)90542-1. · DOI
  2. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embry- onic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 1995; 11:155-63; PMID:7550343; DOI:10.1038/ng1095-155. · DOI
  3. Zhang Y, Li M, Drozda M, Chen M, Ren S, Mejia Sanchez RO, et al. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem 2003; 87:101-6; PMID:12969257; DOI:10.1046/ j.1471-4159.2003.01980.x. · DOI
  4. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000; 20:3705-13; PMID:10804212.
  5. Rigamonti D, Sipione S, Goffredo D, Zuccato C, Fossale E, Cattaneo E. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 2001; 276:14545-8; PMID:11278258; DOI:10.1074/jbc.C100044200. · DOI
  6. Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR. Wild-type hun- tingtin reduces the cellular toxicity of mutant hun- tingtin in vivo. Am J Hum Genet 2001; 68:313-24; PMID:11133364; DOI:10.1086/318207. · DOI
  7. Ho LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mamma- lian cell models of Huntington's disease. J Med Genet 2001; 38:450-2; PMID: 11432963; DOI:10.1136/ jmg.38.7.450. · DOI
  8. Auerbach W, Hurlbert MS, Hilditch-Maguire P, Wadghiri YZ, Wheeler VC, Cohen SI, et al. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum Mol Genet 2001; 10:2515-23; PMID:11709539; DOI:10.1093/hmg/10.22.2515. · DOI
  9. Godin JD, Colombo K, Molina-Calavita M, Keryer G, Zala D, Charrin BC, et al. Huntingtin is required for mitotic spindle orientation and mammalian neuro- genesis. Neuron 2010; 67:392-406; PMID: 20696378; DOI:10.1016/j.neuron.2010.06.027. · DOI
  10. Lee ST, Chu K, Im WS, Yoon HJ, Im JY, Park JE, et al. Altered microRNA regulation in Huntington's disease models. Exp Neurol 2010; 227:172-9; PMID: 21035445; DOI:10.1016/j.expneurol.2010.10.012. · DOI · Paper page
  11. Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME. Enhanced Akt signaling is an early pro-sur- vival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock- in striatal cells. J Biol Chem 2003; 278:50514-22; PMID:14522959; DOI:10.1074/jbc.M309348200. · DOI
  12. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, et al. Specific progressive cAMP reduc- tion implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 2003; 12:497-508; PMID:12588797; DOI:10.1093/ hmg/ddg046. · DOI
  13. Lee JM, Ivanova EV, Seong IS, Cashorali T, Kohane I, et al. Unbiased gene expression analysis impli- cates the huntingtin polyglutamine tract in extra- mitochondrial energy metabolism. PLoS Genet 2007; 3:135; PMID:17708681; DOI:10.1371/journal. pgen.0030135. · DOI · Paper page
  14. Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP, Yohrling GJ, et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent man- ner. J Neurosci 2008; 28:10720-33; PMID:18923047; DOI:10.1523/JNEUROSCI.2126-08.2008. · DOI
  15. Hébert SS, Horré K, Nicolaï L, Bergmans B, Papadopoulou AS, Delacourte A, De Strooper B. MicroRNA regulation of Alzheimer's Amyloid precur- sor protein expression. Neurobiol Dis 2009; 33:422-8; PMID:19110058; DOI:10.1016/j.nbd.2008.11.009. · DOI · Paper page
  16. Patel N, Hoang D, Miller N, Ansaloni S, Huang Q, Rogers JT, et al. MicroRNAs can regulate human APP levels. Mol Neurodegener 2008; 3:10; PMID:18684319; DOI:10.1186/1750-1326-3-10. · DOI
  17. Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. Repression of α-synuclein expression and toxicity by miR-7. Proc Natl Acad Sci USA 2009; 106:13046-51; PMID:19628698; DOI:10.1073/ pnas.0906277106. · DOI · Paper page
  18. Lee Y, Samaco RC, Gatchel JR, Thaller C, Orr HT, Zoghbi HY. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci 2008; 11:1137-9; PMID:18758459; DOI:10.1038/nn.2183. · DOI
  19. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, et al. Dominant pheno- types produced by the HD mutation in STHdh (Q111) striatal cells. Hum Mol Genet 2000; 9:2799-809; PMID:11092756; DOI:10.1093/hmg/9.19.2799. · DOI
  20. Hsu SD, Chu CH, Tsou AP, Chen SJ, Chen HC, Hsu PW, et al. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res 2008; 36:165-9; PMID:18029362; DOI:10.1093/nar/ gkm1012. · DOI
  21. Rehmsmeier M, Steffen P, Höchsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004; 10:1507-17; PMID:15383676; DOI:10.1261/rna.5248604. · DOI · Paper page
  22. Miranda K, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the identification of microRNA-target sites and their cor- responding heteroduplexes. Cell 2006; 126:1203-17; PMID:16990141; DOI:10.1016/j.cell.2006.07.031. · DOI · Paper page
  23. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet 2009; 10:94-108; PMID:19148191; DOI:10.1038/nrg2504. · DOI
  24. Majumder P, Raychaudhuri S, Chattopadhyay B, Bhattacharyya NP. Increased caspase-2, calpain activa- tions and decreased mitochondrial complex II activ- ity in cells expressing exogenous Huntingtin exon 1 containg CAG repeat in the pathogenic range. Cell Mol Neurobiol 2007; 27:1127-45; PMID:17902043; DOI:10.1007/s10571-007-9220-7. · DOI
  25. Raychaudhuri S, Sinha M, Mukhopadhyay D, Bhattacharyya NP. HYPK, a Huntingtin interacting protein, reduces aggregates and apoptosis induced by N-terminal Huntingtin with 40 glutamines in Neuro2a cells and exhibits chaperone-like activity. Hum Mol Genet 2008; 17:240-55; PMID:17947297; DOI:10.1093/hmg/ddm301. · DOI
  26. Baquet ZC, Gorski JA, Jones KR. Early stria- tal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cor- tical brain-derived neurotrophic factor. J Neurosci 2004; 24:4250-8; PMID:15115821; DOI:10.1523/ JNEUROSCI.3920-03.2004. · DOI · Paper page
  27. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST/ NRSF to modulate the transcription of NRSE- controlled neuronal genes. Nat Genet 2003; 35:76-83; PMID:12881722; DOI:10.1038/ng1219. · DOI · Paper page
  28. Xie Y, Hayden MR, Xu B. BDNF Overexpression in the Forebrain Rescues Huntington's Disease Phenotypes in YAC128 Mice. The Journal of Neuroscience 2010; 30:14708-18; DOI:10.1523/ JNEUROSCI.1637-10.2010. · DOI · Paper page
  29. Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM, et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995; 269:407-10; PMID:7618107; DOI:10.1126/ science.7618107. References · DOI · Paper page
  30. Liu J. Control of protein synthesis and mRNA degradation by microRNAs. Curr Opin Cell Biol 2008; 20:214-21; PMID:18329869; DOI:10.1016/j. ceb.2008.01.006. · DOI
  31. Schratt G. Fine-tuning neural gene expression with microRNAs. Curr Opin Neurobiol 2009; 19:213-9; Epub 2009 Jun 17; PMID:19539460; DOI:10.1016/j. conb.2009.05.015. · DOI
  32. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microR- NAs. Genome Res 2009; 19:92-105; PMID:18955434; DOI:10.1101/gr.082701.108. · DOI · Paper page
  33. Ruepp A, Kowarsch A, Schmidl D, Buggenthin F, Brauner B, Dunger I, et al. PhenomiR: a knowledge- base for microRNA expression in diseases and biological processes. Genome Biol 2009; 11:6; PMID:20089154; DOI:10.1186/gb-2010-11-1-r6. · DOI
  34. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, et al. miR2Disease: a manually curated data- base for microRNA deregulation in human disease. Nucleic Acids Res 2009; 37:98-104; PMID:18927107; DOI:10.1093/nar/gkn714. · DOI
  35. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-83; PMID:8458085; DOI:10.1016/0092-8674(93)90585-E. · DOI · Paper page
  36. Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, Buckley NJ. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis 2008; 29:438-45; PMID:18082412; DOI:10.1016/j.nbd.2007.11.001. · DOI · Paper page
  37. Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA miR-9/miR- 9* regulates REST and CoREST and is downreg- ulated in Huntington's disease. J Neurosci 2008; 28:14341-6; PMID:19118166; DOI:10.1523/ JNEUROSCI.2390-08.2008. · DOI · Paper page
  38. Johnson R, Buckley NJ. Gene dysregulation in Huntington's disease: REST, microRNAs and beyond. Neuromolecular Med 2009; 11:183-99; PMID:19458943; DOI:10.1007/s12017-009-8063-4. · DOI
  39. Sinha M, Ghose J, Das E, Bhattarcharyya NP. Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR- 146a targets TBP. Biochem Biophys Res Commun 2010; 396:742-7; PMID:20451497; DOI:10.1016/j. bbrc.2010.05.007. · DOI
  40. Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001; 10:1441-8; PMID:11448935; DOI:10.1093/hmg/10.14.1441. · DOI
  41. Martí E, Pantano L, Bañez-Coronel M, Llorens F, Miñones-Moyano E, Porta S, et al. A myriad of miRNA variants in control and Huntington's dis- ease brain regions detected by massively parallel sequencing. Nucleic Acids Res 2010; 38:7219-35; PMID:20591823; DOI:10.1093/nar/gkq575. · DOI · Paper page
  42. Cha JH. Transcriptional signatures in Huntington's disease. Prog Neurobiol 2007; 83:228-48; PMID:17467140; DOI:10.1016/j.pneuro- bio.2007.03.004. · DOI
  43. Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, Rose C, et al. Huntington's disease: from pathol- ogy and genetics to potential therapies. Biochem J 2008; 412:191-209; PMID:18466116; DOI:10.1042/ BJ20071619. · DOI · Paper page
  44. Vilardo E, Barbato C, Ciotti M, Cogoni C, Ruberti F. MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. J Biol Chem 2010; 285:18344-51; PMID:20395292; DOI:10.1074/jbc. M110.112664. · DOI
  45. Peltier HJ, Latham GJ. Normalization of microR- NA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008; 14:844-52; PMID:18375788; DOI:10.1261/ rna.939908. · DOI · Paper page
  46. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NFkappaB-dependent induction of microRNA miR- 146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103:12481-6; PMID:16885212; DOI:10.1073/ pnas.0605298103. · DOI · Paper page
  47. Kong PJ, Kil MO, Lee H, Kim SS, Johnson GV, Chun W. Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line. Neurol Res 2009; 31:77-83; PMID:18691453; DOI:10.1179/174313208X331572. · DOI
  48. Subramaniam S, Sixt KM, Barrow R, Snyder SH. Rhes, a Striatal Specific Protein, Mediates Mutant- Huntingtin Cytotoxicity. Science 2009; 324:1327-30; PMID:19498170; DOI:10.1126/science.1172871. · DOI
  49. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microR- NAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:179; PMID:16314309; DOI:10.1093/nar/gni178. · DOI
  50. Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson G. Rosiglitazone treatment prevents mito- chondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J Biol Chem 2008; 283:25628- 37; PMID:18640979; DOI:10.1016/j.brainres- bull.2009.07.010. · DOI
  51. Xifró X, García-Martínez JM, Del Toro D, Alberch J, Pérez-Navarro E. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. J Neurochem 2008; 105:596-612; PMID:18221365; DOI:10.1111/ j.1471-4159.2008.05252.x. · DOI

Cited by

Sorted by citations

Metadata

Authors
Sinha, M., Ghose, J., & Bhattarcharyya, N. P.
Venue
RNA Biology
Publisher
Informa UK Limited
Published
2011-11
Volume
8
Issue
6
Pages
1005-1021
ISSN
  • 1547-6286
  • 1555-8584
DOI
10.4161/rna.8.6.16035
Cited by
75
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review